Abcam, ab100632, Human RAGE ELISA Kit

Size: 1 x 96Tests
Human RAGE ELISA Kit is a Sandwich (quantitative) ELISA for the measurement of Human RAGE in Human in Biofluids, Cell Culture Media samples.
Key facts
Detection method:Colorimetric,
Sample types:Plasma, Cell culture supernatant, Serum,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:< 3 pg/mL,
Range:2.06 - 1500 pg/mL,
Assay Platform:Microplate

Product details:
Abcam's RAGE Human ELISA (Enzyme-Linked Immunosorbent Assay) kit is an
in vitro
enzyme-linked immunosorbent assay for the quantitative measurement of Human RAGE in serum, plasma and cell culture supernatants.
This assay employs an antibody specific for Human RAGE coated on a 96-well plate. Standards and samples are pipetted into the wells and RAGE present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Human RAGE antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of RAGE bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
Get higher sensitivity in only 90 minutes with Human RAGE ELISA Kit (
ab190807
) from our SimpleStep ELISA
range.
Optimization may be required with urine samples.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
RAGE also known as Receptor for Advanced Glycation End-products is a multi-ligand cell surface receptor with a molecular weight of approximately 45 kDa. It belongs to the immunoglobulin superfamily consisting of three extracellular immunoglobulin-like domains a transmembrane domain and a cytoplasmic tail. RAGE is widely expressed in various tissues throughout the body with high expression levels in the lungs heart and cells of the nervous system. The receptor can interact with several ligands such as advanced glycation end-products (AGEs) amyloid beta and S100/calgranulin proteins facilitating signal transduction into the cells.
Biological function summary
RAGE functions in the immune and inflammatory response where it mediates cell signaling that leads to cellular activation and the release of pro-inflammatory cytokines. It acts as part of complexes with different proteins contributing to cellular processes such as proliferation and migration. RAGE also plays roles in the regulation of oxidative stress and apoptosis impacting cellular health and survival. Researchers employ tools like 'anti-RAGE' antibodies and 'RAGER ELISA' assays to measure and study RAGE expression levels and its interactions in various experimental setups.
Pathways
RAGE is significantly involved in the NF-kB pathway and the MAPK signaling cascade. Its activation can lead to the release of NF-kB a transcription factor that plays an essential role in immune and inflammatory responses. RAGE interacts with proteins such as p38 MAPK leading to a cascade of events that regulate inflammation and stress responses. The signaling pathways involving RAGE are important in maintaining cell homeostasis and responding to cellular stressors and tools like 'anti-RAGE' and 'mouse RAGE' antibodies serve to elucidate these complex pathways further.
RAGE has strong associations with chronic diseases like diabetes and Alzheimer's disease. In diabetes RAGE binds to AGEs contributing to inflammation and vascular complications where it often interacts with proteins like iNOS and VEGF. In Alzheimer's disease RAGE is implicated in the accumulation and toxicity of amyloid-beta peptides interacting with proteins such as APP and tau. Understanding RAGE's role in these diseases can aid in developing therapeutic strategies employing reagents such as 'phen RAGE' and 'anti-RAGE' for targeted treatment approaches.